A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor

NCT05148442 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped Due to the company's development strategy adjustment\]

Conditions

Myeloid Tumor

Interventions

DRUG: IBI322

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.